MTAP欠損変異を有する固形癌の相手をするメチオニンアデノシルトランスフェラーゼ2A（MAT2A）阻害剤SYH2039の全世界権利を間もなくBeOne Medicinesへと社名変更するBeiGene社がCSPC Zhongqi Pharmaceuticalから手に入れます。
MTAP欠損は癌全体のおよそ15%にどうやら認められます。特に膠芽腫、膵癌、非小細胞肺癌（NSCLC）で多く見受けられます。
BeiGene社は手持ちのPRMT5阻害剤BGB-58067とSYH2039の併用の検討に特に期待を寄せています。
SYH2039のPh1試験がClinicaltrials.govに登録されています。まだ準備段階らしく、被験者組み入れはまだ始まっていない（Not yet recruiting）と記されています。
MAT2A阻害剤といえばIdeaya Biosciences社がこの7月に有望なPh2試験結果を報告しています。先立ってさんざっぱら治療された（heavily pre-treated）MTAP欠損尿路上皮癌/非小細胞肺癌患者18人の4割弱（7/18人）にIDE397が奏効しました。
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
SAN MATEO, Calif.–(BUSINESS WIRE)–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors.
SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in approximately 15 percent of all cancer types with the most common including glioblastoma, pancreatic cancer and non-small cell lung cancer.
“With one of the most dynamic solid tumor portfolios in the industry, we are continually assessing opportunities that align with our strategic focus and address significant unmet needs for patients. This MAT2A inhibitor is a valuable addition to our solid tumor pipeline, and we’re eager to explore its potential, particularly in combination with our internally developed PRMT5 inhibitor, BGB-58067. Together, these assets hold promise for advancing treatment across a range of solid tumors,” said Lai Wang, Ph.D., Global Head of R&D at BeiGene.
BGB-58067, which is on track to enter the clinic before the end of the year, is designed to avoid on-target hematological toxicity seen with first-generation PRMT5 inhibitors. It has best-in-class potential with high potency, selectivity, and brain penetrability.
Under the terms of the agreement, BeiGene has an exclusive license to develop, manufacture and commercialize SYH2039 worldwide. CSPC will receive upfront and time-based payments totaling $150 million and will be eligible for payments upon the achievement of certain development and commercial milestones and tiered royalties.
BeiGene is focused on growing its leadership in solid tumors with its PD-1 inhibitor TEVIMBRA® (tislelizumab) and by advancing potential best-in-class assets for lung, breast and gastrointestinal cancers, including several differentiated antibody drug conjugates, multi-specific antibodies, targeted protein degraders, and small molecule inhibitors. The Company recently announced its intent to change its name to BeOne, reaffirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible.
コメント